Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linvoseltamab versus daratumumab in high-risk smoldering multiple myeloma
2025-523252-31-00Phase 3Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, open-label trial in smoldering multiple myeloma (SMM) comparing Linvoseltamab with Daratumumab (2 arms). Primary endpoints: Clinical progression-free survival and Biochemical progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
linvoseltamabdaratumumab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on 2025-523252-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523252-31-00.